PMC7083210_01
PMC7083210_02
PMC7083210_03
(A) Revised ALS Functional Rating Scale (ALSFRS-R) was determined at the given time-points before and after 1 month of Fasudil infusions. Patient A and C had a more aggressive disease progression of >1 point decline per month while patient B showed a decline of only 1 point over 3 months. In all three patients, ALSFRS-R progression was attenuated significantly during and shortly after Fasudil infusions. (B) In patient B, Motor unit index (MUNIX) was measured in the given arm muscles before and at the end of 1 month Fasudil infusions as well as 3 and 6 months after the first day of infusion. MUNIX was increased in 5 of 6 measured muscles after 4 weeks of Fasudil treatment. At the follow-up visits at 3 and 6 months, MUNIX gradually decreased again in all measured muscles. APB, abductor pollicis brevis muscle; ADM, adductor digiti minimi muscle; BB, biceps brachii muscle. (C) Patient A had a severely impaired respiratory function with a slow vital capacity (SVC) of only 800 ml (26% of normal) at the start of Fasudil treatment. SVC was measured daily during the 20 consecutive working days of Fasudil infusions. It increased to 1,900 ml at the end of the treatment.
fneur-11-00173-g0002.jpg
PMC7083210_13_fneur-11-00173-g0002.jpg
F2
The neurological examination remained stable, so did the ALSFRS-R at 37 points (Figure 2) and the SVC at 2,800 ml.
PMC7083210_04
PMC7083210_05
PMC7083210_06
PMC7083210_07
PMC7083210_08
In all patients, arterial systolic (A) and diastolic (B) blood pressure and heartrate (C) were measured at the given time-points before, during and after start of the 45 min Fasudil infusion. In patient A (left column), this monitoring was done regularly on the first 3 days of infusion. Here, all data are shown in the graphs. For patients B (middle column) and C (right column) monitoring was conducted during every infusion. Here, only the data from the morning infusion of every fifth day are given. While patient A and B were hypertonic especially at the beginning of each infusion, no significant or clinically relevant changes in blood pressure or heart rate were noted.
fneur-11-00173-g0001.jpg
PMC7083210_11_fneur-11-00173-g0001.jpg
F1
Blood pressure and heartrate were measured every 10-15 min before, during and after the infusion of Fasudil on every day of infusion (Figure 1).
PMC7083210_09
(A) Revised ALS Functional Rating Scale (ALSFRS-R) was determined at the given time-points before and after 1 month of Fasudil infusions. Patient A and C had a more aggressive disease progression of >1 point decline per month while patient B showed a decline of only 1 point over 3 months. In all three patients, ALSFRS-R progression was attenuated significantly during and shortly after Fasudil infusions. (B) In patient B, Motor unit index (MUNIX) was measured in the given arm muscles before and at the end of 1 month Fasudil infusions as well as 3 and 6 months after the first day of infusion. MUNIX was increased in 5 of 6 measured muscles after 4 weeks of Fasudil treatment. At the follow-up visits at 3 and 6 months, MUNIX gradually decreased again in all measured muscles. APB, abductor pollicis brevis muscle; ADM, adductor digiti minimi muscle; BB, biceps brachii muscle. (C) Patient A had a severely impaired respiratory function with a slow vital capacity (SVC) of only 800 ml (26% of normal) at the start of Fasudil treatment. SVC was measured daily during the 20 consecutive working days of Fasudil infusions. It increased to 1,900 ml at the end of the treatment.
fneur-11-00173-g0002.jpg
PMC7083210_13_fneur-11-00173-g0002.jpg
F2
The neurological examination remained stable, so did the ALSFRS-R at 37 points (Figure 2) and the SVC at 2,800 ml.
PMC7083210_10
PMC7083210_11
In all patients, arterial systolic (A) and diastolic (B) blood pressure and heartrate (C) were measured at the given time-points before, during and after start of the 45 min Fasudil infusion. In patient A (left column), this monitoring was done regularly on the first 3 days of infusion. Here, all data are shown in the graphs. For patients B (middle column) and C (right column) monitoring was conducted during every infusion. Here, only the data from the morning infusion of every fifth day are given. While patient A and B were hypertonic especially at the beginning of each infusion, no significant or clinically relevant changes in blood pressure or heart rate were noted.
fneur-11-00173-g0001.jpg
PMC7083210_11_fneur-11-00173-g0001.jpg
F1
Blood pressure and heartrate were measured every 10-15 min before, during and after the infusion of Fasudil on every day of infusion (Figure 1).
PMC7083210_12
PMC7083210_13
(A) Revised ALS Functional Rating Scale (ALSFRS-R) was determined at the given time-points before and after 1 month of Fasudil infusions. Patient A and C had a more aggressive disease progression of >1 point decline per month while patient B showed a decline of only 1 point over 3 months. In all three patients, ALSFRS-R progression was attenuated significantly during and shortly after Fasudil infusions. (B) In patient B, Motor unit index (MUNIX) was measured in the given arm muscles before and at the end of 1 month Fasudil infusions as well as 3 and 6 months after the first day of infusion. MUNIX was increased in 5 of 6 measured muscles after 4 weeks of Fasudil treatment. At the follow-up visits at 3 and 6 months, MUNIX gradually decreased again in all measured muscles. APB, abductor pollicis brevis muscle; ADM, adductor digiti minimi muscle; BB, biceps brachii muscle. (C) Patient A had a severely impaired respiratory function with a slow vital capacity (SVC) of only 800 ml (26% of normal) at the start of Fasudil treatment. SVC was measured daily during the 20 consecutive working days of Fasudil infusions. It increased to 1,900 ml at the end of the treatment.
fneur-11-00173-g0002.jpg
PMC7083210_13_fneur-11-00173-g0002.jpg
F2
The neurological examination remained stable, so did the ALSFRS-R at 37 points (Figure 2) and the SVC at 2,800 ml.
PMC7083210_14
PMC7083210_15